Preclinical studies conducted using a PTEN-deficient murine prostate cancer model and human prostate cancer xenografts showed that inhibiting both the PI3K/AKT and AR pathways had profound tumor regression compared to inhibiting a single pathway [2]. This evidence concerns the gene PTEN and prostate cancer.